BNP (B-type Natriuretic Peptide) vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | Cagrilintide |
|---|---|---|
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |